Eurocor enters the market with their FREEWAY™ COATED SHUNT BALLOON CATHETER
High pressure balloon is recommended for the treatment of AV fistulas and shunt grafts as it reduces re-intervention and preserves future treatment options
Bonn Sept 15, 2016
Eurocor, a global leader in medical DEB-technology, services and solutions, today announced that the FREEWAY™ – SHUNT BALLOON CATHETER (DEB) has been placed in the market for arteriovenous (AV) access to help patients with end-stage renal disease.
Following the first release on the launch of AV Fistula balloon, we are glad to announce that first 500 units had been manufactured and international shipment against orders been executed. The feedback from the physicians on the usage is very positive and we received good demand from different markets.
The balloon is indicated for Patients who undergo dialysis as they suffer from end stage renal failure. Stenosis and subsequent restenosis of the dialysis shunt graft is a common complication. The treatment of this stenosis is mandatory to protect AV fistulas and shunt grafts from early restenosis
FREEWAY™ – SHUNT DEB protects AV fistulas and shunt grafts from early restenosis and is a clinical proven therapeutically effective option for AV shunt patients. A feasibility study presented at LINC 2015, showed a low re-intervention rate of 11% at follow up.
“We are thrilled to promote our third generation catheters for treatment of AV Fistula through our existing / new distributors and showcase our product in leading hospitals in major markets and regions around the world”, says CEO of Eurocor GmbH, Lalit Mamtani
Eurocor’s second-generation drug-eluting technology PTA balloon FREEWAY has been developed as an alternative to the limitations of existing therapeutic to PAD e.g. restenosis after POBA or stenting. The product provides excellent crossability, trackability and pushability and can be used where the use of other therapies is limited by the occurrence of high restenosis rates, anatomical challenges and stent fractures.
The coating makes the difference – FREEWAY uses a proprietary homogenous coating
Eurocor’s DEB technology utilises a homogenous drug coating, which is released when the balloon is expanded. This inhibits the proliferation of smooth muscle cells, and may prevent restenosis by disturbing microtubule formation and thereby inhibiting cell division and migration. Paclitaxel is applied in a final concentration of 3 μg/mm² to the surface of the balloon.
• Clinically proven robust coating, with no drug loss on the way to target.
• Balloon lengths of 20 - 150 mm for Ø 2.0-8.0 mm with different shaft lengths
• Excellent catheter flexibility with tapered, hydrophilic shafts and low tip entry profiles
Phone: +49 (0) 228 201 500
Eurocor is a rapidly growing European Life Sciences Technology Corporation specializing in the research, development and manufacture of cardiovascular and endovascular products. Eurocor provides interventional physicians with innovative coronary stent technologies and special cardiovascular and endovascular devices, manufactured in Bonn. Products are indicated for minimally invasive cardiovascular and peripheral surgery and comply with biological and biomechanical principles to offer highly flexible, adaptable solutions. Extensive research and development, close clinician collaboration, outstanding quality standard philosophy and global scientific alliances lead to optimization of clinically effective technologies. Eurocor has designed an innovative method for balloon catheter drug delivery with high patient compliance. One heartbeat ahead® – with innovative products such as DIOR® and FREEWAY™.
Eurocor GmbH is a wholly owned subsidiary of Opto Eurocor Healthcare Limited and is part of the Opto Circuits Group.
For more information, please visit eurocor.de and optocircuits.com.